Dr. Yang Xu 徐泱
Chief Physician, Associate Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of liver tumors, including hepatocellular carcinoma, cholangiocarcinoma, hemangioma, cysts, adenoma, FNH, AML, hilar cholangiocarcinoma, and metastatic liver cancer from colorectal, gastric, or lung origins. Liver transplantation.
Dr. Xu is a Chief Physician and Associate Professor at Zhongshan Hospital, Fudan University. A postdoctoral fellow at Johns Hopkins Hospital, Dr. Xu conducted research at Queen Mary Hospital, University of Hong Kong, in 2001. Research focuses on liver cancer stem cells and transplantation. Dr. Xu has performed over 7,000 liver and general surgeries and participated in over 300 liver transplants. Dr. Xu helped establish the Shanghai Fudan Standard for liver transplantation indications.
Name order: in Chinese the family name comes first (Xu Yang). Papers usually list the name as Yang Xu or Xu Y.
Selected publications
76 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Biomed, 2026 (first author): Generalizable cancer detection from ultra-low-pass WGS via deep contextual modeling of cfDNA sequences. PubMed 42584731
- Biol Proced Online, 2026 (senior author): A novel prognostic model based on MVIRGs identifies ANGPT2 as a key target driving the malignant progression of HCC. PubMed 42215875
- Biochem Pharmacol, 2025 (senior author): Nur77 inhibits mitochondrial excessive fragmentation through mutated p53 L194F in T47D breast cancer cells. PubMed 40414511
- J Cancer Res Clin Oncol, 2024 (senior author): Effects of the subtypes of apolipoprotein E on immune inhibition and prognosis in patients with Hepatocellular Carcinoma. PubMed 38976030
- Genomics Proteomics Bioinformatics, 2021 (senior author): The mRNA-miRNA-lncRNA Regulatory Network and Factors Associated with Prognosis Prediction of Hepatocellular Carcinoma. PubMed 33741523
- J Cancer, 2020 (senior author): MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. PubMed 32201518
- Future Oncol, 2019 (senior author): Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. PubMed 31729887
- Oncotarget, 2017 (senior author): Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis. PubMed 29254221
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion